» Articles » PMID: 33767664

Fluorescence-Guided High-Grade Glioma Surgery More Than Four Hours After 5-Aminolevulinic Acid Administration

Overview
Journal Front Neurol
Specialty Neurology
Date 2021 Mar 26
PMID 33767664
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Fluorescence-guided surgery (FGS) using 5-aminolevulic acid (5-ALA) is a widely used strategy for delineating tumor tissue from surrounding brain intraoperatively during high-grade glioma (HGG) resection. 5-ALA reaches peak plasma levels ~4 h after oral administration and is currently approved by the FDA for use 2-4 h prior to induction to anesthesia. To demonstrate that there is adequate intraoperative fluorescence in cases undergoing surgery more than 4 h after 5-ALA administration and compare survival and radiological recurrence to previous data. Retrospective analysis of HGG patients undergoing FGS more than 4 h after 5-ALA administration was performed at two institutions. Clinical, operative, and radiographic pre- and post-operative characteristics are presented. Sixteen patients were identified, 6 of them female (37.5%), with mean (SD) age of 59.3 ± 11.5 years. Preoperative mean modified Rankin score (mRS) was 2 ± 1. All patients were dosed with 20 mg/kg 5-ALA the morning of surgery. Mean time to anesthesia induction was 425 ± 334 min. All cases had adequate intraoperative fluorescence. Eloquent cortex was involved in 12 cases (75%), and 13 cases (81.3%) had residual contrast enhancement on postoperative MRI. Mean progression-free survival was 5 ± 3 months. In the study period, 6 patients died (37.5%), mean mRS was 2.3 ± 1.3, Karnofsky score 71.9 ± 22.1, and NIHSS 3.9 ± 2.4. Here we demonstrate that 5-ALA-guided HGG resection can be performed safely more than 4 h after administration, with clinical results largely similar to previous reports. Relaxation of timing restrictions could improve procedure workflow in busy neurosurgical centers, without additional risk to patients.

Citing Articles

Emerging nanoplatforms towards microenvironment-responsive glioma therapy.

Tripathy N, Sahoo L, Paikray S, Dilnawaz F Med Oncol. 2025; 42(2):46.

PMID: 39812745 DOI: 10.1007/s12032-024-02596-y.


Enhancing Glioblastoma Resection with NIR Fluorescence Imaging: A Systematic Review.

Mansour H, Shah S, Aguilar T, Abdul-Muqsith M, Gonzales-Portillo G, Mehta A Cancers (Basel). 2024; 16(23).

PMID: 39682171 PMC: 11639985. DOI: 10.3390/cancers16233984.


Combined use of 5-ALA-induced protoporphyrin IX and chlorin e6 for fluorescence diagnostics and photodynamic therapy of skin tumors.

Efendiev K, Alekseeva P, Skobeltsin A, Shiryaev A, Pisareva T, Akhilgova F Lasers Med Sci. 2024; 39(1):266.

PMID: 39477891 DOI: 10.1007/s10103-024-04219-4.


Intraoperative Fluorophores: An Update on 5-Aminolevulinic Acid and Sodium Fluorescein in Resection of Tumors of the Central Nervous System and Metastatic Lesions-A Systematic Review and Meta-Analysis.

Shah S, Ivey N, Matur A, Andaluz N Tomography. 2023; 9(5):1551-1567.

PMID: 37736977 PMC: 10514891. DOI: 10.3390/tomography9050124.


Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).

Yalamarty S, Filipczak N, Li X, Subhan M, Parveen F, Ataide J Cancers (Basel). 2023; 15(7).

PMID: 37046777 PMC: 10093719. DOI: 10.3390/cancers15072116.


References
1.
Johansson A, Palte G, Schnell O, Tonn J, Herms J, Stepp H . 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol. 2010; 86(6):1373-8. DOI: 10.1111/j.1751-1097.2010.00799.x. View

2.
Colditz M, van Leyen K, Jeffree R . Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: theoretical, biochemical and practical aspects. J Clin Neurosci. 2012; 19(12):1611-6. DOI: 10.1016/j.jocn.2012.03.013. View

3.
Kaneko S, Kaneko S . Fluorescence-Guided Resection of Malignant Glioma with 5-ALA. Int J Biomed Imaging. 2016; 2016:6135293. PMC: 4939363. DOI: 10.1155/2016/6135293. View

4.
Stummer W, Suero Molina E . Fluorescence Imaging/Agents in Tumor Resection. Neurosurg Clin N Am. 2017; 28(4):569-583. DOI: 10.1016/j.nec.2017.05.009. View

5.
Orringer D, Lau D, Khatri S, Zamora-Berridi G, Zhang K, Wu C . Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012; 117(5):851-9. DOI: 10.3171/2012.8.JNS12234. View